Last update: April 19, 2018
Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.
We do not have alternatives for Estradiol Enantate.
Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Estradiol Enantate is also known as Estradiol. Here it is a list of alternative known names::
Estradiol Enantate in other languages or writings:
Main tradenames from several countries containing Estradiol Enantate in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | Oral: 5 | % |
Molecular weight | 272 | daltons |
Protein Binding | 98 | % |
Tmax | 1 - 4 | hours |
T1/2 | 20 - 26 | hours |
M/P ratio | 0,1 | - |
Write to us at elactancia.org@gmail.com
e-lactancia is a resource recommended by La Liga de la Leche, España from Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
A natural Estrogen that is marketed for oral, injection and topical administration (skin and vaginal).
On the chemical form of valerate, it is used in association with a progestin as a combined birth-control compound (e.g. Estradiol + Dienogest)
Estradiol is excreted into breast milk in clinically non-significant amount (Nilson 1978) and no problems have been observed in infants whose mothers were treated (Pinheiro 2016). Plasma levels of these infants were undetectable or very low (Pinheiro 2016). After administration in the form of transdermal patches milk levels have been undetectable (Pinheiro 2016, Perheentupa 2004). Despite these data, an older publication associated the use of transdermal estradiol with a case of jaundice and poor weight gain (Ball 1999).
There is greater passage to milk when the administration is vaginal.
There is evidence (albeit inconsistent) that estrogen-containing pills may decrease milk production, especially during the first few weeks postpartum
They may reduce the protein content of the milk.
No problems have been observed in infants whose mothers were treated, except some cases of transient gynecomastia in infants whose mothers were receiving a higher dose than usual.
Estrogen exposure in childhood or adolescence, does not influence the subsequent production of milk.
The American Academy of Pediatrics states that this medication is usually compatible with breastfeeding.
See below the information of this related product: